Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sun Pharmaceutical Industries Limited: Clinical Trials & FDA Approval Profile

Sun Pharmaceutical Industries Limited (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 6 active protocols (2 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)10.0%
Median Closed Enrollment vs National (145 pts)262 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sun Pharmaceutical Industries Limited
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)6 (2)
Completed vs Stopped Early12 / 2 (10.0%)
Median Closed Actual Enrollment262 participants
Physical Hospital Site Disclosure85.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Sun Pharmaceutical Industries Limited
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05422911Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.Phase IIRECRUITING
NCT06611163A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.Phase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Sun Pharmaceutical Industries Limited Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI